Achieving complete pathologic response in esophageal adenocarcinoma is linked to a notable survival benefit. Among 16,169 patients analyzed, 11.4% achieved this response, rising to 17.5% in those diagnosed from 2016 to 2020. Key independent predictors included female sex, black race, Hispanic ethnicity, and clinical stage II disease, while clinical stage III correlated with lower response probabilities. Median survival was 86.4 months for responders versus 30.7 months for non-responders, highlighting critical prognostic implications.
Journal Article by Donato BB, Campany ME (…) D’Cunha J et 5 al. in Dis Esophagus
© The Author(s) 2024. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.